Perioperative Padcev and Keytruda Improves Survival in MIBC

Keytruda and Padcev Generate Positive Topline Findings in Bladder Cancer

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Perioperative Padcev and Keytruda improves survival in MIBC

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.The post Perioperative Padcev and Keytruda improves survival in MIBC appeared first on Clinical Trials Arena.

Perioperative EV plus pembrolizumab significantly extends EFS, OS in MIBC

An interim analysis of the data showed that the trial met its primary end point of EFS, as well as the key secondary end points of OS and pCR rate.